Araştırma Makalesi

Outcomes of intravenous thrombolytic therapy in cardioembolic strokes

Cilt: 5 Sayı: 2 1 Şubat 2021
PDF İndir
EN

Outcomes of intravenous thrombolytic therapy in cardioembolic strokes

Öz

Background/Aim: It is controversial whether intravenous recombinant tissue plasminogen activator (IV r-tPA) treatment outcomes in cardioembolic strokes differ from other types of strokes. This study aims to investigate the clinical data of patients with cardioembolic and large-vessel atherosclerosis who received IV r-tPA treatment and compare and discuss the results according to the literature. Methods: The data of the patients who were admitted within the first 4.5 hours following the onset of symptoms, diagnosed with acute ischemic stroke in the Neurology clinic of Kütahya Evliya Çelebi Training and Research Hospital and underwent IV r-tPA were evaluated in this retrospective cohort study. Demographic data, clinical and functional results of patients were compared between the two groups (cardioembolic and large vessel atherosclerosis). Results: Eighty-five patients with ischemic stroke who received IV r-tPA treatment due to cardioembolism and large-vessel atherosclerosis were included in the study. There were 51 patients (60%) in the cardioembolic stroke group and 34 patients (40%) in the large vascular atherosclerotic group. There was no significant difference in terms of functional results between the groups (62.7% vs 44.1%; P=0.09). While symptomatic intracerebral hemorrhage was not detected in the large-vessel atherosclerosis group, it occurred in 3.9% of the cardioembolic stroke group. Conclusion: This study proved that functional and clinical results are similar between cardioembolic and large-vessel atherosclerosis patients who were treated with IV r-tPA treatment. Regardless of the etiology, all suitable patients with acute ischemic stroke should be treated with thrombolytic therapy.

Anahtar Kelimeler

Kaynakça

  1. 1. Ois A, Cuadrado-Godia E, Rodriguez-Campello A, Giralt-Steinhauer E, Jiménez-Conde J, Lopez-Cuiña M, et al. Relevance of stroke subtype in vascular risk prediction. Neurology. 2013;81:571-80.
  2. 2. Wei W, Li S, San F, Zhang S, Shen Q, Guo J, et al. Retrospective analysis of prognosis and risk factors of patients with stroke by TOAST. Medicine (Baltimore). 2018:97:e0412.
  3. 3. The National Institute of Neurological Disorder and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333:1581-7.
  4. 4. Hacke W, Kaste M, Fieschi C, von Kummer R, Davalos A, Meier D, et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators. Lancet 1998;352:1245-51.
  5. 5. Timsit SG, Sacco RL, Mohr JP, Foulkes MA, Tatemichi TK, Wolf PA, et al. Brain infarction severity differs according to cardiac or arterial embolic source. Neurology. 1993;43:728-33.
  6. 6. Molina CA, Montaner J, Arenillas JF, Ribo M, Rubiera M, Sabín JA. Differential pattern of tissue plasminogen activator-induced proximal middle cerebral artery recanalization among stroke subtypes. Stroke. 2004;35:486-90.
  7. 7. Rocha S, Pires A, Gomes J, Rocha J, Sousa F, Pinho J, et al. Intravenous thrombolysis is more effective in ischemic cardioembolic strokes than in non-cardioembolic? Arq Neuro psiquiatr. 2011;69:905-9.
  8. 8. Nam HS, Lee KY, Kim YD, Choi HY, Cho HJ, Cha MJ, et al. Failure of complete recanalization is associated with poor outcome after cardioembolic stroke. Eur J Neurol. 2011;18:1171-8.

Ayrıntılar

Birincil Dil

İngilizce

Konular

Nöroloji ve Nöromüsküler Hastalıklar

Bölüm

Araştırma Makalesi

Yayımlanma Tarihi

1 Şubat 2021

Gönderilme Tarihi

3 Ekim 2020

Kabul Tarihi

21 Şubat 2021

Yayımlandığı Sayı

Yıl 2021 Cilt: 5 Sayı: 2

Kaynak Göster

APA
Çetiner, M., Seyit, M., Eşkut, N., Akdağ, G., Akkoyun, F., & Canbaz Kabay, S. (2021). Outcomes of intravenous thrombolytic therapy in cardioembolic strokes. Journal of Surgery and Medicine, 5(2), 111-114. https://doi.org/10.28982/josam.801301
AMA
1.Çetiner M, Seyit M, Eşkut N, Akdağ G, Akkoyun F, Canbaz Kabay S. Outcomes of intravenous thrombolytic therapy in cardioembolic strokes. J Surg Med. 2021;5(2):111-114. doi:10.28982/josam.801301
Chicago
Çetiner, Mustafa, Murat Seyit, Neslihan Eşkut, Gönül Akdağ, Fatma Akkoyun, ve Sibel Canbaz Kabay. 2021. “Outcomes of intravenous thrombolytic therapy in cardioembolic strokes”. Journal of Surgery and Medicine 5 (2): 111-14. https://doi.org/10.28982/josam.801301.
EndNote
Çetiner M, Seyit M, Eşkut N, Akdağ G, Akkoyun F, Canbaz Kabay S (01 Şubat 2021) Outcomes of intravenous thrombolytic therapy in cardioembolic strokes. Journal of Surgery and Medicine 5 2 111–114.
IEEE
[1]M. Çetiner, M. Seyit, N. Eşkut, G. Akdağ, F. Akkoyun, ve S. Canbaz Kabay, “Outcomes of intravenous thrombolytic therapy in cardioembolic strokes”, J Surg Med, c. 5, sy 2, ss. 111–114, Şub. 2021, doi: 10.28982/josam.801301.
ISNAD
Çetiner, Mustafa - Seyit, Murat - Eşkut, Neslihan - Akdağ, Gönül - Akkoyun, Fatma - Canbaz Kabay, Sibel. “Outcomes of intravenous thrombolytic therapy in cardioembolic strokes”. Journal of Surgery and Medicine 5/2 (01 Şubat 2021): 111-114. https://doi.org/10.28982/josam.801301.
JAMA
1.Çetiner M, Seyit M, Eşkut N, Akdağ G, Akkoyun F, Canbaz Kabay S. Outcomes of intravenous thrombolytic therapy in cardioembolic strokes. J Surg Med. 2021;5:111–114.
MLA
Çetiner, Mustafa, vd. “Outcomes of intravenous thrombolytic therapy in cardioembolic strokes”. Journal of Surgery and Medicine, c. 5, sy 2, Şubat 2021, ss. 111-4, doi:10.28982/josam.801301.
Vancouver
1.Mustafa Çetiner, Murat Seyit, Neslihan Eşkut, Gönül Akdağ, Fatma Akkoyun, Sibel Canbaz Kabay. Outcomes of intravenous thrombolytic therapy in cardioembolic strokes. J Surg Med. 01 Şubat 2021;5(2):111-4. doi:10.28982/josam.801301